INTRODUCTION:

The analysis and interpretation of data produced during pre-clinical and clinical studies are known as pharmacometrics. In preclinical and clinical pharmacology, pharmacokinetics, pharmacodynamic, and toxicological investigations, several forms of experimental data are typically collected on individuals and populations of natural medicines, as well as on animals or human beings.¹

Understanding the underlying knowledge, such as biostatistics, computational systems, and modelling of pharmacokinetic/pharmacodynamics is necessary to apply methods of analysis of similar data. Pharmacometrics-trained scientists contribute to the design and analysis of protocols and studies about drug remedy issues and provide insight into the mechanisms that govern the time course of dose concentration. Furthermore, pharmacologic, toxicologic, and clinical reactions.²

Pharmacometrics relies on information development, knowledge discovery, the use of instructive visualisations, and the understanding of biomarkers and surrogate endpoints. In this, pharmacometrics entails the formulation or assessment of pharmacokinetic, pharmacodynamic, pharmacodynamic -outcomes linking, and disease progression models. To better comprehend the effects of various dosage strategies, patient selection criteria, distinct endpoints, and various statistical approaches, those modes can be linked and applied to conflicting study designs.³

Clinical pharmacology with a quantitative perspective is what pharmacometrics is all about. Since more than 20 years ago, pharmacometrics—pharmacokinetics/ pharmacodynamics (PK/PD) modelling and simulation—have been used to guide drug development decisions, and the pharmaceutical sector, academic institutions, and regulatory organisations have all shown increased support for this approach. Currently, pharmacometrics analysis is crucial at every stage of the drug development process, from the early translational stage to the confirmatory phase 3 and regulatory approval, and even into the post-marketing study.⁴

Understanding the variability in drug response is one of the pharmacometrics' main goals. Variability may be predictable (due to variations in body weight or renal function, for example) or seemingly unexpected (a reflection of the current lack of knowledge). Our current foundation for data sciences in clinical pharmacology, drug research, and development is the application of mathematical models and statistical approaches.⁵

Pharmacometrics' primary goal is to offer data that is pertinent to the pursuit of safety and efficacy advancements in pharmacotherapy. "The science of developing and applying mathematical and statistical methods to characterise, understand, and predict a drug's pharmacokinetic and pharmacodynamic behaviour, (b) quantify the uncertainty of information about that behaviour, and (c) rationalise data-driven decision making in the drug development process and pharmacotherapy, " according to the definition of pharmacometrics (PMx).⁶

The relationship between pharmacometrics and pharmacodynamics is provided through a mathematical and statistical model used in pharmacometrics. The recent founding of the International Society of Pharmacometrics underlines the "coming of age" of pharmacometrics as a global subject. This review is meant to be used in the context of the pharmacometrics model and its application to regulatory decisions and the preclinical and clinical phases of drug development.⁷

History:

Pharmacometrics (PMx) was first studied before 1960. One of the cutting-edge techniques to describe patterns in observational data since the 1970s is the modelling and simulation of pharmacokinetic and pharmacodynamic processes.⁸

Model-based drug development is promoted in a white paper by FDA titled "Challenge and Opportunity on the Critical Path to New Products, " which was issued in 2004. (MBDD). Since then, pharmacometrics analysis has grown in significance as a part of New Drug Application (NDA) and Biological License Application (BLA) submissions to the FDA for decisions about drug approval, labelling, and trial design.⁹

Models:

Models are typically simplified representations of systems, and it is this simplification that allows them to be useful in providing knowledge and understanding of the system. Models, in their broadest sense, are representations of a "system" that are intended to provide knowledge or understanding of the system. Models have typically simplified representations of complex systems, and it is this simplification that allows them to be useful. The nature of the simplification is related to the model's intended use.¹⁰

Models offer a framework for defining the time course of drug exposure and reaction following the administration to persons of various doses or formulations of a drug. They also offer a way to estimate associated parameters, such as clearance and volume of distribution of a drug. A strategy for determining and outlining connections between a subject's physiological variables and their reported drug exposure or response is population modelling.¹¹

These models' mechanistic nature enables a thorough description of the supporting network of natural processes and how they react to corrective actions. Thus, less sophisticated models that are nonetheless useful for describing the dynamic nature of supporting natural systems have been growing wider acceptance. This obstacle can be solved with the aid of mathematical modelling and simulation tools, which can be used to combine data from many in vitro, animal, and clinical investigations into a single, overarching model¹².

Figure 1: Types of Modeling

It has been discovered that model-based drug development addresses the underlying reasons why drugs fail, hence increasing the productivity, effectiveness, and success of late-stage clinical development. Additionally, the Act offers a mechanism to encourage dialogue between regulatory scientists and drug developers to support model-informed drug development in particular development programmes.¹³

Pharmacokinetic models:

Pharmacokinetics is the study of an ADME process in a medication.. Pharmacokinetics is the study of the drug's ADME over time and how that relates to both its therapeutic and harmful effects. Clinical pharmacology is the application of the pharmacokinetic model's principles to maximising drug dosage to meet the demands of specific patients and maximise therapeutic value. Pharmacokinetic interactions occur when one medicine or substance affects the distribution, metabolism, excretion, and absorption of the target drug.¹⁴

The pharmacokinetic model is a concise way of expressing the time course of drugs throughout the body mathematically or quantitatively and computing meaningful pharmacokinetic parameters. It is a mathematical analysis of the process ADME. The combination of clinical pharmacology and mathematical modelling, the so-called pharmacokinetic modelling, was brought to the next level by applying the statistical mixed-effects method.¹⁵

Methods for analysis of PK Data:

Compartment model:

A compartmental model is a mathematical model that simulates how people in different "compartments" of a population interact with one another. It is also referred to as the empirical model. This model simply interpolates the experimental data and allows an empirical formula to be used to analyse the drug concentration over time. Many PK models start with a "compartment"—a region of the body where the drug is well mixed and kinetically homogeneous.¹⁶

Physiological model:

A physiologically based pharmacokinetic model is another name for this model (PB-PK models). The use of physiologically based pharmacokinetic and pharmacodynamics (PBPK/PD) modelling to aid in the prevention of adverse drug events, drug-drug interactions, and drug-disease interactions has grown in popularity. PBPK modelling is a predictive tool that can be used to influence drug choice, selection, and routes of administration in various ethnic populations, as well as populations of varying ages and disease stages.¹⁷

Non-compartmental analysis:

This analysis is model-independent. The area under the curve (AUC), the area under the first moment curve (AUMC), clearance (CL), mean residence time (MRT), terminal half-life (t1/2), and volume of distribution are all frequently determined using non-compartmental analysis (Vd). This methodology can be used with any Compartment model because it is predicated on the idea that medicines or their metabolites exhibit linear kinetics. It is frequently used to calculate bioavailability, clearance, and apparent volume of distribution.¹⁸

Pharmacodynamics model:

Pharmacodynamics is the study of how a drug affects the body. It relates response to drug concentration in the body. It is concerned with the drug's biochemical and physiological effects, as well as its mode of action. Variability in pharmacodynamics is caused by differences in the effect produced by a given drug concentration. Models that relate pharmacological effect to drug concentration in plasma or at the effector site. The activity of the object drug at its site of action is altered by another drug in pharmacodynamic interactions.¹⁹

Common model types discussed include simple direct effects, biophase distribution, indirect effects, signal transduction, and irreversible effects. Pharmacodynamics modeling's main goals are to integrate known system components, functions, and constraints, to generate and test competing hypotheses of drug mechanisms and system responses under new conditions, and to estimate system-specific parameters that may be inaccessible.²⁰

In this subject, biomarkers can be divided into two main categories: (1) predictive biomarkers, which include any assessments of response, lack of response, or toxicity, and (2) mechanism-of-action biomarkers, which offer details about a drug's PD effects.²¹

Pharmacokinetic /pharmacodynamics (PKPD) model:

A drug concentration in the body results from the "processing of a drug by the body, " or pharmacokinetics (PK). Similar to pharmacodynamics (PD), which is defined as "how the medicine operates on the body, " pharmacological effects are quantifiable. Both pharmacokinetic and pharmacodynamic modelling are combined in this modelling.²²

A mathematical link between plasma drug concentration and pharmacological response is known as PK/PD modelling. To better understand the relationship between exposure PK and drug response PD and how those interactions alter as a result of drug consumption, this model is utilised in the creation of new medications.²³

The relationship between drug exposure and response can be quantified using PK and PD models, which can also be used to characterise the effects of characteristics relevant to the drug, delivery mechanism, physiological system, and pathological system on this relationship. This PK and PD link model is directly connected to an effect site through a measured concentration.²⁴ In translational drug research, PK/PD modelling is a promising strategy that offers a better knowledge of therapeutic efficacy and safety. Specific expressions for the characterization of processes on the causal pathway between drug exposure and drug response are found in mechanism-based PK-PD models.²⁵

Disease Progression models:

An essential part of medication research and pharmacology is the study of illness progression using disease progression models. Using mathematical operations to statistically explain the course of a disease's progression is known as disease modelling. They can be used to identify whether a medicine demonstrates symptomatic activity or slows progression by being connected to a contemporaneous PK model. With Nick Holford's seminal work on ADASC in Alzheimer's disease in 1992, the value of linking disease progression models with clinical trial simulations has been understood.²⁶

These early instances showed how to evaluate illness development through clinical outcomes and the advantages of doing so. Decisions on choosing a pathway and target, choosing a candidate, choosing a biomarker technique, choosing a patient, and choosing the best study design are all influenced by mechanistic-based models. mathematical illustrations showing the progression and condition of an illness throughout time. Treatments for degenerative disorders can be divided into symptomatic and protective types. Preventative care can sluggish, stop, or even stop the progression of the disease. Treatments focused on symptoms can only work to lessen symptoms.²⁷

To characterise the natural progression of the disease, disease models may include biomarkers of disease severity and/or clinical outcomes. There are three types of disease progression models: empirical, semi-mechanistic, and systems biology.

Empirical models – It is purely data-driven and does not describe underlying biological processes; instead, it serves as a mathematical framework for interpolation between observed data.

Systems biology - Disease progression models are physiologically based and incorporate as much molecular detail as possible in mathematical representations of biological, pathophysiological, and pharmacological processes.

Semi-mechanistic - Models fall between the empirical and systems biology poles.

Understanding the development of disease requires an approach like this. It guides various applications' extrapolation ideas (pediatric drug development, rare diseases, etc.) Optimize the design of clinical trials by helping with dose, duration, visits, treatment arms, etc. Endpoint qualification for biomarkers and (surrogates).²⁸

Population Pharmacokinetic Model:

Population pharmacokinetics (PK) modelling is not a brand-new idea; Sheiner et al. first discussed it in 1972. The alterations in characteristics like population size and age distribution within a population are of interest to population modelling. Population modelling is a technique for figuring out and describing connections between the physiological traits of a patient and observed drug exposure or reaction.

Component of population modeling-

i. Preparation of Data and Databases.

ii. Structural models as an algebraic equation.

iii. Superposition and linearity.

iv. The use of differential equations in structural models.

v. Stochastic models for random effects.

vi. Models using covariates for fixed effects.

vii. Population modeling requires accurate information on dosing, measurements, and covariates.

viii. Population models are comprised of several components: structural models, stochastic models, and covariate models.²⁹

Accurate dosage, measurement, and covariate information are necessary for population modelling. Structural models, stochastic models, and covariate models are some of the parts that make up population models. Structural models are functions that describe the temporal evolution of a measured response. They can be expressed as algebraic or differential equations. While stochastic models describe the variability or random effects in the observable data, covariate models show how factors like demography or disease affect each time course of the response.³⁰

The study of drug pharmacokinetic variations among various demographic groups is known as population pharmacokinetics. Parameters in population models include the likelihood of survival, productivity, and population growth rate. Including stochasticity improves the precision, realism, and utility of population models. Pharmacokinetic, pharmacodynamic, and PK/PD models all involve population modeling. This paradigm is applied to clinical procedures and medication development.³¹

Pharmacometrics in drug development and clinical trial:

Pharmacometrics aims to create models that provide guidance and decision support for drug development, including trial design, efficacy comparisons, dosage regimen optimization, and endpoint analysis, as well as for supporting regulatory decisions and enhancing clinical care for particular patient populations.

Figure 2: Drug development and clinical trial

Every stage of drug development, from molecular screening to post-marketing surveillance, can benefit from the application of pharmacometrics. The establishment of fundamental knowledge regarding a disease, the discovery of potential remedies, the engineering of processes for drug production, and the carrying out of tests to prove safety and efficacy are all necessary for the development of a new commercial drug product.³²

Drug PKs (i.e., absorption, distribution, elimination, and exposure) prediction has advanced far more than PDs in terms of drug development (i.e., efficacy and safety). The use of these predictions to calculate dosage in patients not included in phase III trials has utility because medication exposure frequently corresponds with efficacy and safety.³³

Preclinical trial:

Preclinical pharmacometrics' major function is to define the exposure-response connections for both efficacy and toxicity. Preclinical development should play a significant part in this process. Drug potency and intrinsic activity can be determined based on concentrations rather than doses thanks to the evaluation of dose-concentration-response correlations in preclinical drug development in animal models, which accounts for pharmacokinetic differences between diverse substances.³⁴Before testing, it is crucial to assess the PK/PD characteristics of possible compounds, simulate potential dose–concentration–efficacy–toxicity correlations, and finally, support the choice of the dosages chosen for early clinical testing. To project the expected human dose and/or dosing regimen, a mix of MandS techniques, including population analysis of limited preclinical PK data, allometric scaling to forecast human PK, and empirical efficacy scaling, can be applied.

OBJECTIVES:

The demonstration of biological activity in disease-related experimental animal models.

The accumulation of toxicological data to justify the initial human dosage.

Based on required qualities, select a lead candidate or candidates.

Modeling and simulation:

· Guide the developmental strategy with integrated decision-making criteria.

· Begin assessing biomarker performance about decision criteria.

· Construct and analyse PK/PD experiments.

· Use in vivo/in vitro data to predict human clearance.

· Estimate efficacy (potency, EC50) using preclinical exposure-response and comparator data.

· Determine the margin of safety based on toxicology studies' target "efficacy" concentrations and exposure data.

For phase I studies, PK/PD modelling was used to help with dose selection.³⁵

Clinical trial:

The goal of clinical pharmacy management is to provide the greatest possible patient outcomes by promoting the pharmaceutical care philosophy and integrating a compassionate attitude with professional therapeutic knowledge, experience, and judgement. For the sake of enhancing people's health and quality of life, the clinical pharmacy must promote new knowledge.³⁶

CONCLUSION:

In these review articles, the developing field of research known as pharmacometrics measures data on drugs, diseases, and clinical trials to help with successful drug development and regulatory principles was determined. Commonly, pharmacometrics models are data-driven and developed relying on robust statistical models/ algorithms derived to describe data and rigorously assess the ability of the developed models to reproduce the observed data. Clinical pharmacists and Pharmacologists with this knowledge are ideally placed to influence clinical management using pharmacometrics principles. In these, the pharmacometrics helps to determine the efficacy, toxicity, safety, Dose adjustment, Dose-response relationship, and disease-related variability by models. The scope of these models extended beyond the small homogenous studies with the adoption of econometric and biometric methods as novel tools in clinical trials. Model-informed drug development (MIDD) is expected to play an increasingly prominent role in future drug development and regulatory decision-making. Which we can reduce in vivo and clinical drug testing and it builds for a future increase in the number of effective treatments for patients. Despite its possible advantages and numerous applications, does not offer the perfect solution, and there is still a lack of prospective.

REFERENCES:

1. Bhavatharini PA, Deepalakshmi M, Arun KP. Pharmacometrics: The science applied from bench to bedside. Journal of Applied Pharmaceutical Science. 2021 Dec 27; 12(1):055-64.

2. Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. The Journal of Clinical Pharmacology. 2008 May; 48(5):632-49.

3. Ette EI, Williams PJ, editors. Pharmacometrics: the science of quantitative pharmacology. John Wiley and Sons; 2013 Mar 14.

4. Xu Y, Kimko H. Pharmacometrics: A quantitative decision-making tool in drug development. Quantitative Methods in Pharmaceutical Research and Development: Concepts and Applications. 2020:71-104.

5. Koch G, Pfister M, Daunhawer I, Wilbaux M, Wellmann S, Vogt JE. Pharmacometrics and machine learning partner to advance clinical data analysis. Clinical Pharmacology and Therapeutics. 2020 Apr; 107(4):926-33.

6. van der Graaf PH. CPT: pharmacometrics and systems pharmacology. CPT: Pharmacometrics and Systems Pharmacology. 2012 Sep; 1(9):1-4.

7. Yeo KR, Hennig S, Krishnaswami S, Strydom N, Ayyar VS, French J, Sinha V, Sobie E, Zhao P, Friberg LE, Mentré F. CPT: Pharmacometrics and Systems Pharmacology–inception, maturation, and future vision. CPT: Pharmacometrics and Systems Pharmacology. 2021 Jul; 10(7):649.

8. Lee SJ, Jeon S. A review of three years' experience of the first pharmacometrics company in Korea. Translational and Clinical Pharmacology. 2019 Dec; 27(4):149-54.

9. Zheng QS, Li LJ. Pharmacometrics: a quantitative tool of pharmacological research. Acta Pharmacologica Sinica. 2012 Nov; 33(11):1337-8.

10. Frigg R, Hartmann S. Models in science (Stanford encyclopedia of philosophy).

11. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: Pharmacometrics and Systems Pharmacology. 2012 Sep; 1(9):1-4..

12. Zhang XY, Trame MN, Lesko LJ, Schmidt S. Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT: Pharmacometrics and Systems Pharmacology. 2015 Feb; 4(2):69-79.

13. Srinivasan M, White A, Chaturvedula A, Vozmediano V, Schmidt S, Plouffe L, Wingate LM. Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development. Pharmacoeconomics. 2020 Oct; 38:1031-42.

14. Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. Vallabh Prakashan. Edition 3, 238-247.

15. Koch G, Pfister M, Daunhawer I, Wilbaux M, Wellmann S, Vogt JE. Pharmacometrics and machine learning partner to advance clinical data analysis. Clinical Pharmacology and Therapeutics. 2020; 107(4):926-33.

16. Towers S. Introduction to compartmental modeling. Polymatheia. Archived from the original on December. 2013; 11.

17. Perry C, Davis G, Conner TM, Zhang T. Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: an overview. Current Pharmacology Reports. 2020; 6:71-84.

18. Rohatagi S, Kan S, Derendorf H. Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. Die Pharmazie. 1997; 52(7):529-32.

19. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition. 2003; 31(5):510-8.

20. Felmlee, M. A., Morris, M. E., and Mager, D. E. Mechanism-based pharmacodynamic modeling. Methods in molecular biology (Clifton, N.J.); 2012: 929, 583–600.

21. Garralda E, Dienstmann R, Tabernero J. Pharmacokinetic /pharmacodynamic modeling for drug development in oncology. American Society of Clinical Oncology Educational Book. 2017; 37:210-5.

22. Zou H, Banerjee P, Leung SS, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Frontiers in Pharmacology. 2020; 11: 997.

23. Derendorf H, Meibohm B. Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharmaceutical Research. 1999 Feb; 16:176-85.

24. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics. Drug Discovery Today. 2007; 12(23-24):1018-24.

25. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences. 2008; 29(4):186-91.

26. Holford NH, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proceedings of the National Academy of Sciences. 1992; 89(23):11471-5.

27. Barrett JS, Nicholas T, Azer K, Corrigan BW. Role of disease progression models in drug development. Pharmaceutical Research. 2022; 39(8):1803-15.

28. Cook SF, Bies RR. Disease progression modeling: key concepts and recent developments. Current Pharmacology Reports. 2016 Oct; 2:221-30.

29. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharmaceutical Research. 1995; 12:1845-55.

30. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: Pharmacometrics and Systems Pharmacology. 2012; 1(9):1-4.

31. Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO. A population pharmacokinetic-pharmacodynamic model of pegfilgrastim. The AAPS Journal. 2018; 20(5):91.

32. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011; 100(1):4-17.

33. Powell JR, Cook J, Wang Y, Peck R, Weiner D. Drug dosing recommendations for all patients: a roadmap for change. Clinical Pharmacology and Therapeutics. 2021; 109(1):65-72.

34. Williams PJ, Ette EI. Pharmacometrics: impacting drug development and pharmacotherapy. Pharmacometrics: The Science of Quantitative Pharmacology. 2007 Mar 23:1-21.

35. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/ pharmacodynamics and the stages of drug development: role of modeling and simulation. The AAPS Journal. 2005 ; 7:E544-59.

36. Ella R Assessment of Pharmacometrics and Clinical Pharmacy. J Pharma Reports. 2022; 06:153.

37. Aarons L, Karlsson MO, Mentré F, Rombout F, Steimer JL, van Peer A. Role of modelling and simulation in Phase I drug development. European Journal of Pharmaceutical Sciences. 2001; 13(2):115-22.

38. Sheiner LB. Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics. 1997; 61(3): 275-91.

39. Alsultan A, Alghamdi WA, Alghamdi J, Alharbi AF, Aljutayli A, Albassam A, Almazroo O, Alqahtani S. Clinical pharmacology applications in clinical drug development and clinical care: a focus on Saudi Arabia. Saudi Pharmaceutical Journal. 2020; 28(10): 1217-27.

Received on 05.04.2023 Modified on 10.06.2023

Asian J. Pharm. Ana. 2023; 13(3):210-216.

DOI: 10.52711/2231-5675.2023.00034